Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

ENSOMA

Company Type: Therapeutics

Main focus: In vivo editing via virus-like particles (VLPs) and adenovirus

Company stage: Pre-clinical

Diseases: Targeting any cell of the haematopoietic system to cure diseases from within

Genome-editing tool: Cas12a ( from Twelve Bio)

Funding stage: Series B

Location: Boston USA

Website: ensoma.com

Pipeline:

Partners:

Ensoma is a pre-clinical-stage company that aims to engineer directly haematopoeitic stem cells, T cells and other immune cell types, in vivo, by delivering a genome editor via their proprietary virus-like-particles (VLPs) platform, which is also known as Engenious.

Ensoma

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...

CMN Weekly (7 February 2025) - Your Weekly CRISPR...